Xuanzhu Biopharm Maintains 517.95 Million H-Share Capital in June; Public Float Meets 24.96% Requirement

Bulletin Express

07/07

Xuanzhu Biopharmaceutical Co., Ltd. reported no movements in share capital during June 2026. Issued H shares remained at 517.95 million, each with a par value of RMB 1, keeping registered share capital steady at RMB 517.95 million.

All 517.95 million H shares are listed on the Hong Kong Stock Exchange, and the company held no treasury shares at month-end. The public float continues to satisfy the initial prescribed threshold, confirmed at 24.96 % of total issued H shares.

The filing notes no share options, warrants, convertibles, or other equity arrangements outstanding or exercised during the month.

Joint Company Secretary He Chengming submitted the monthly return to the Exchange on 7 July 2026.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1126665105"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1126665105\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1126665105?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-07 17:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126665105","market":"us","top_or_hot":-1,"title":"Xuanzhu Biopharm Maintains 517.95 Million H-Share Capital in June; Public Float Meets 24.96% Requirement","media":"Bulletin Express","content":"<p>Xuanzhu Biopharmaceutical Co., Ltd. reported no movements in share capital during June 2026. Issued H shares remained at 517.95 million, each with a par value of RMB 1, keeping registered share capital steady at RMB 517.95 million.</p>\n<p>All 517.95 million H shares are listed on the Hong Kong Stock Exchange, and the company held no treasury shares at month-end. The public float continues to satisfy the initial prescribed threshold, confirmed at 24.96 % of total issued H shares.</p>\n<p>The filing notes no share options, warrants, convertibles, or other equity arrangements outstanding or exercised during the month.</p>\n<p>Joint Company Secretary He Chengming submitted the monthly return to the Exchange on 7 July 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xuanzhu Biopharm Maintains 517.95 Million H-Share Capital in June; Public Float Meets 24.96% Requirement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXuanzhu Biopharm Maintains 517.95 Million H-Share Capital in June; Public Float Meets 24.96% Requirement\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-07-07 17:06</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Xuanzhu Biopharmaceutical Co., Ltd. reported no movements in share capital during June 2026. Issued H shares remained at 517.95 million, each with a par value of RMB 1, keeping registered share capital steady at RMB 517.95 million.</p>\n<p>All 517.95 million H shares are listed on the Hong Kong Stock Exchange, and the company held no treasury shares at month-end. The public float continues to satisfy the initial prescribed threshold, confirmed at 24.96 % of total issued H shares.</p>\n<p>The filing notes no share options, warrants, convertibles, or other equity arrangements outstanding or exercised during the month.</p>\n<p>Joint Company Secretary He Chengming submitted the monthly return to the Exchange on 7 July 2026.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02575","symbol_name":"軒竹生物-B","start_time":0,"source_url":"","article_id":"1126665105","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126665105","pubTimestamp":1783415163,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Xuanzhu Biopharmaceutical Co., Ltd. reported no movements in share capital during June 2026. Issued H shares remained at 517.95 million, each with a par value of RMB 1, keeping registered share...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02575":"轩竹生物-B"},"translate_title":"轩竹生物6月维持H股股本5.1795亿股；公众持股量满足24.96%要求","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02575":1},"content_text":"Xuanzhu Biopharmaceutical Co., Ltd. reported no movements in share capital during June 2026. Issued H shares remained at 517.95 million, each with a par value of RMB 1, keeping registered share capital steady at RMB 517.95 million.\nAll 517.95 million H shares are listed on the Hong Kong Stock Exchange, and the company held no treasury shares at month-end. The public float continues to satisfy the initial prescribed threshold, confirmed at 24.96 % of total issued H shares.\nThe filing notes no share options, warrants, convertibles, or other equity arrangements outstanding or exercised during the month.\nJoint Company Secretary He Chengming submitted the monthly return to the Exchange on 7 July 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}